These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 27548074)

  • 1. Rivaroxaban versus Heparin Bridging to Warfarin Therapy: Impact on Hospital Length of Stay and Treatment Costs for Low-Risk Patients with Pulmonary Embolism.
    Weeda ER; Kohn CG; Peacock WF; Fermann GJ; Crivera C; Schein JR; Coleman CI
    Pharmacotherapy; 2016 Oct; 36(10):1109-1115. PubMed ID: 27548074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is Rivaroxaban Associated With Shorter Hospital Stays and Reduced Costs Versus Parenteral Bridging to Warfarin Among Patients With Pulmonary Embolism?
    Coleman CI; Fermann GJ; Weeda ER; Wells PS; Ashton V; Crivera C; Bunz TJ; Wildgoose P; Schein JR; Peacock WF
    Clin Appl Thromb Hemost; 2017 Oct; 23(7):830-837. PubMed ID: 27481875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hospital length-of-stay and costs among pulmonary embolism patients treated with rivaroxaban versus parenteral bridging to warfarin.
    Weeda ER; Wells PS; Peacock WF; Fermann GJ; Baugh CW; Ashton V; Crivera C; Wildgoose P; Schein JR; Coleman CI
    Intern Emerg Med; 2017 Apr; 12(3):311-318. PubMed ID: 27757790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation status.
    Weeda ER; Peacock WF; Fermann GJ; Baugh CW; Wells PS; Ashton V; Crivera C; Wildgoose P; Schein JR; Coleman CI
    Int J Clin Pract; 2017 Jan; 71(1):. PubMed ID: 28097761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost of Treating Venous Thromboembolism With Heparin and Warfarin Versus Home Treatment With Rivaroxaban.
    Kahler ZP; Beam DM; Kline JA
    Acad Emerg Med; 2015 Jul; 22(7):796-802. PubMed ID: 26111453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary Embolism Inpatients Treated With Rivaroxaban Had Shorter Hospital Stays and Lower Costs Compared With Warfarin.
    Margolis JM; Deitelzweig S; Kline J; Tran O; Smith DM; Crivera C; Bookhart B; Schein J
    Clin Ther; 2016 Nov; 38(11):2496-2503. PubMed ID: 27751675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studies.
    Kohn CG; Fermann GJ; Peacock WF; Wells PS; Baugh CW; Ashton V; Crivera C; Schein JR; Wildgoose P; Coleman CI
    Curr Med Res Opin; 2017 Sep; 33(9):1697-1703. PubMed ID: 28665208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healthcare costs associated with rivaroxaban or warfarin use for the treatment of venous thromboembolism.
    Coleman CI; Baugh C; Crivera C; Milentijevic D; Wang SW; Lu L; Nelson WW
    J Med Econ; 2017 Feb; 20(2):200-203. PubMed ID: 27780397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overall Effectiveness of Rivaroxaban in Patients with Pulmonary Embolism.
    Wang L; Baser O; Wells P; Peacock WF; Coleman CI; Fermann GJ; Schein J; Crivera C
    Clin Ther; 2017 Jul; 39(7):1426-1436.e2. PubMed ID: 28652016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis Admissions.
    Margolis JM; Deitelzweig S; Kline J; Tran O; Smith DM; Bookhart B; Crivera C; Schein J
    J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27792638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cost-analysis model for anticoagulant treatment in the hospital setting.
    Mody SH; Huynh L; Zhuo DY; Tran KN; Lefebvre P; Bookhart B
    J Med Econ; 2014 Jul; 17(7):492-8. PubMed ID: 24773068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban Versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting.
    Deitelzweig S; Laliberté F; Crivera C; Germain G; Bookhart BK; Olson WH; Schein J; Lefebvre P
    Clin Ther; 2016 Aug; 38(8):1803-1816.e3. PubMed ID: 27491278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute pulmonary embolism treatment with rivaroxaban results in a shorter duration of hospitalisation compared to standard therapy: an academic centre experience.
    Paczyńska M; Kurnicka K; Lichodziejewska B; Goliszek S; Dzikowska-Diduch O; Sobieraj P; Burzyński Ł; Kostrubiec M; Pruszczyk P; Ciurzyński M
    Kardiol Pol; 2016; 74(7):650-6. PubMed ID: 26779849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients.
    Knight KK; Wong J; Hauch O; Wygant G; Aguilar D; Ofman JJ
    Value Health; 2005; 8(3):191-200. PubMed ID: 15877591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter Trial of Rivaroxaban for Early Discharge of Pulmonary Embolism From the Emergency Department (MERCURY PE): Rationale and Design.
    Singer AJ; Xiang J; Kabrhel C; Merli GJ; Pollack C; Tapson VF; Wildgoose P; Peacock WF
    Acad Emerg Med; 2016 Nov; 23(11):1280-1286. PubMed ID: 27537530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Healthcare resource utilization and costs associated with venous thromboembolism in cancer patients treated with anticoagulants.
    Streiff M; Milentijevic D; McCrae KR; Laliberté F; Lejeune D; Lefebvre P; Schein J; Khorana AA
    J Med Econ; 2019 Nov; 22(11):1134-1140. PubMed ID: 31106638
    [No Abstract]   [Full Text] [Related]  

  • 17. Costs of hospital visits among patients with deep vein thrombosis treated with rivaroxaban and LMWH/warfarin.
    Merli GJ; Hollander JE; Lefebvre P; Laliberté F; Raut MK; Germain G; Bookhart B; Pollack CV
    J Med Econ; 2016; 19(1):84-90. PubMed ID: 26390315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization.
    Bullano MF; Willey V; Hauch O; Wygant G; Spyropoulos AC; Hoffman L
    J Manag Care Pharm; 2005 Oct; 11(8):663-73. PubMed ID: 16194130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apixaban or Rivaroxaban Versus Warfarin for Treatment of Submassive Pulmonary Embolism After Catheter-Directed Thrombolysis.
    Groetzinger LM; Miller TJ; Rivosecchi RM; Smith RE; Gladwin MT; Rivera-Lebron BN
    Clin Appl Thromb Hemost; 2018 Sep; 24(6):908-913. PubMed ID: 29455567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy.
    Spyropoulos AC; Frost FJ; Hurley JS; Roberts M
    Chest; 2004 May; 125(5):1642-50. PubMed ID: 15136371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.